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Abstract
Purpose—Pancreatic cysts are estimated to be present 2–3% of the adult population. 
Unfortunately, current diagnostics do not accurately distinguish benign cysts from those that can 
progress into invasive cancer. Missregulated pericellular proteolysis is a hallmark of malignancy, 
and therefore, we used a global approach to discover protease activities that differentiate benign 
nonmucinous cysts from premalignant mucinous cysts.
Experimental Design—We employed an unbiased and global protease profiling approach to 
discover protease activities in 23 cyst fluid samples. The distinguishing activities of select 
proteases was confirmed in 110 samples using specific fluorogenic substrates and required less 
than 5 µL of cyst fluid.
Results—We determined that the activities of the aspartyl proteases gastricsin and cathepsin E 
are highly increased in fluid from mucinous cysts. Immunohistochemical analysis revealed that 
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gastricsin expression was associated with regions of low-grade dysplasia, whereas cathepsin E 
expression was independent of dysplasia grade. Gastricsin activity differentiated mucinous from 
nonmucinous cysts with a specificity of 100% and a sensitivity of 93%, whereas cathepsin E 
activity was 92% specific and 70% sensitive. Gastricsin significantly outperformed the most 
widely used molecular biomarker, carcinoembryonic antigen (CEA), which demonstrated 94% 
specificity and 65% sensitivity. Combined analysis of gastricsin and CEA resulted in a near perfect 
classifier with 100% specificity and 98% sensitivity.
Conclusions—Quantitation of gastricsin and cathepsin E activities accurately distinguished 
mucinous from nonmucinous pancreatic cysts and has the potential to replace current diagnostics 
for analysis of these highly prevalent lesions.
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Introduction
The detection of pancreatic cysts has increased dramatically due to the rising use of high-
resolution abdominal imaging. Pancreatic cysts are incidentally detected in 13–45% of 
patients evaluated by magnetic resonance imaging and 2% of patients evaluated by 
computed tomography (1–3). The most frequently detected pancreatic cysts include 
intraductal papillary mucinous neoplasms (IPMNs), mucinous cystic neoplasms (MCNs), 
pseudocysts, and serous cystadenomas (SCAs) (4). Both IPMNs and MCNs, which are 
collectively referred to as mucinous cysts, may develop foci of high-grade dysplasia or 
cancer (5). At the time of resection, ~30% of IPMNs and ~15% of MCNs contain invasive 
cancer (6,7). Pseudocysts and SCAs, which are both nonmucinous, rarely undergo malignant 
degeneration and are considered benign lesions that typically do not require resection or 
continued surveillance. Clinical decision making for pancreatic cysts relies largely on 
radiographic and clinical features, augmented by analysis of cyst fluid collected by 
endoscopic ultrasound with fine needle need aspiration (EUS-FNA) (8). Unfortunately, with 
current clinical guidelines, distinguishing nonmucinous from mucinous cysts remains a 
challenge. The preoperative diagnosis of mucinous cysts is incorrect in up to 30% of cases 
and benign cysts are often resected, exposing patients to an unnecessary risk for morbidity 
(9–12).
As abdominal imaging remains unable to accurately differentiate pancreatic cyst types, there 
has been considerable effort towards developing improved diagnostic biomarkers. Most of 
these biomarkers utilize cyst fluid collected by EUS-FNA. CEA is the most widely 
investigated biomarker and is 60–80% accurate for differentiating mucinous from 
nonmucinous cysts (13,14). KRAS mutations occur in more than 90% of pancreatic cancers 
and are frequently observed in mucinous cysts (15,16). Analysis of cyst fluid DNA revealed 
that KRAS mutations are 100% specific, but only 50% sensitive for diagnosing a mucinous 
cyst (17). Similarly, analysis of mutations in the oncogene GNAS are specific for diagnosing 
IPMNs, but suffer from low sensitivity (18). A variety of other cyst fluid biomarkers have 
also been explored (19–23); however, CEA remains the only widely applied molecular 
biomarker for differentiating mucinous from nonmucinous cysts.
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Proteases mediate a variety of critical processes in cancer, including invasion of the 
basement membrane via cleavage of extracellular matrix proteins and promotion of 
oncogenic signaling pathways through activation of growth factors and receptor tyrosine 
kinases (24,25). In pancreatic cancer, members of the cathepsin family of endolysosomal 
proteases are upregulated and found extracellularly. Aberrant secretion leads to cleavage of 
extracellular substrates, driving increased cellular invasion (26). Either genetic deletion or 
pharmacological inhibition of cysteine cathepsin activity decreases tumor progression and 
invasion (27,28).
Gene expression profiling studies of IPMNs and MCNs indicate overexpression of a range 
of proteases (29–31). Furthermore, analysis of protein expression in cyst fluid showed 
substantial differences in the abundance of pancreatic proteases and their cognate inhibitors 
between cyst types. The serine protease inhibitor SPINK1 was recently investigated as a 
biomarker for differentiating benign from malignant cysts (32,33). Collectively, these results 
suggest that there may be altered levels of proteolytic activity between mucinous and 
nonmucinous cysts and that these differences could be exploited to distinguish the type of 
lesion and its associated malignant potential.
In the current study, we applied a global protease profiling technology to discover 
proteolytic activity markers for differentiating mucinous from nonmucinous cysts. Using this 
approach, we identified enhanced aspartyl protease activity in mucinous cysts, due to 
upregulation of gastricsin and cathepsin E. We characterized the localization of both aspartyl 
proteases within the dysplastic tissue surrounding the mucinous cysts and determined that 
gastricsin expression was dependent on the degree of dysplasia. Lastly, highly selective 
fluorescent substrates for gastricsin and cathepsin E both confirmed their upregulated 
activities and outperformed CEA for differentiating mucinous from nonmucinous pancreatic 
cystic lesions.
Materials and methods
Patients and sample acquisition
Pancreatic cyst fluid samples were collected from preconsented patients under institutional 
review board approved protocols and in accordance with U. S. Common Rule at the 
University of California San Francisco, the University of Pittsburgh Medical Center, Indiana 
University School of Medicine, and Stanford University School of Medicine. Patient 
information is summarized in Table S1. All patients included in our study underwent 
surgical resection of their cystic lesion and have a pathologically confirmed diagnosis. The 
highest grade of dysplasia observed during pathological evaluation of each cystic lesion is 
reported. Samples were collected either at the time of surgical resection or during diagnostic 
endoscopic ultrasound prior to resection of the cystic lesion. Cyst fluid samples were split 
into 100 µL aliquots and frozen to −80 °C within 60 minutes of collection. Samples 
underwent at most two freeze-thaw cycles prior to experimental analysis. Total cyst fluid 
protein concentration was determined by the bicinchoninic acid assay. CEA levels were 
evaluated for the majority of samples, but were unavailable in 21 cases due to limited cyst 
fluid volume.
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Multiplex substrate profiling by mass spectrometry (MSP-MS) assay
The MSP-MS assay was performed as previously described (34). Cyst fluid was diluted to 
100 µg/mL in assay buffer (either pH 7.5 phosphate buffer or pH 3.5 acetate buffer) and pre-
incubated for 10 minutes. For analysis of protease inhibitor sensitivity, 1 mM AEBSF 
(Sigma, A8456), 2 µM E-64 (Sigma, E3132), 2 µM pepstatin (Sigma, P5318), 2 mM 1,10-
phenanthroline (Sigma, 131337), or DMSO were included in pre-incubation. The 228 
tetradecapeptide library was split into two pools and diluted in assay buffer to a 
concentration of 1 µM of each peptide. 75 µL of diluted cyst fluid and peptide pools were 
then combined and incubated at room temperature. 30 µL aliquots were removed after 15 
and 60 minutes, protease activity quenched with 8 M guanidinium hydrochloride, and flash-
frozen in liquid N2. For recombinant gastricsin (R&D Systems, 6186-AS), cathepsin D 
(R&D Systems, 1014-AS), and cathepsin E (R&D Systems, 1294-AS), the MSP-MS assay 
was performed as described above with slight modifications: 10 nM of recombinant protease 
in pH 3.5 acetate buffer was used and aliquots were removed after 15, 60, and 240 minutes.
Prior to peptide cleavage site identification by mass spectrometry, samples were desalted 
using C18 tips (Rainin). Mass spectrometry analysis was carried out with an LTQ Orbitrap 
XL mass spectrometer coupled to a 10,000 psi nanoACQUITY Ultra Performance Liquid 
Chromatography (UPLC) System (Waters) for peptide separation by reverse phase liquid 
chromatography (RPLC). Peptides were separated over a C18 column (Thermo) and eluted 
by applying a flow rate of 300 nL/min with a 65-minute linear gradient from 2–30% 
acetonitrile. Survey scans were recorded over a 325–1500 m/z range and the six most intense 
precursor ions were fragmented by collision-induced dissociation (CID) for MS/MS.
Raw mass spectrometry data was processed to generate peak lists using MSConvert. Peak 
lists were then searched in Protein Prospector v. 5.10.0 (35) against a custom database 
containing the sequences from the 228 tetradecapeptide library. Searches used a mass 
accuracy tolerance of 20 ppm for precursor ions and 0.8 Da for fragment ions. Variable 
modifications included N-terminal pyroglutamate conversion from glutamine or glutamate 
and oxidation of tryptophan, proline, and tyrosine. Searches were subsequently processed 
using the MSP-xtractor software (http://www.craiklab.ucsf.edu/extractor.html), which 
extracts the peptide cleavage site and spectral counts of the corresponding cleavage products. 
Spectral counts were used for the relative quantification of peptide cleavage products.
Proteomic analysis of cyst fluid samples
Cyst fluid samples were processed for proteomic analysis using a standard protocol. Briefly, 
8 µg of cyst fluid protein was denatured in 40 µL of 6 M urea. Disulfide bonds were reduced 
with 10 mM dithiothreitol and free thiols were subsequently alkylated with 12.5 mM 
iodoacetamide. Samples were then diluted to with 25 mM ammonium bicarbonate to 2 M 
urea and digested with 100 ng trypsin for 16 hours at 37 °C. Following trypsin digestion, 
samples were desalted with C18 tips (Rainin), dried, and resuspended in 0.1% formic acid. 
Triplicate LC-MS/MS analysis of all samples was performed as described above and details 
for this and protein identification are provided in the Supplemental Methods and Materials.
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Label-free quantitation was used to compare relative abundance of the three aspartyl 
proteases identified in cyst fluid samples. The Skyline software package was used to obtain 
extracted ion chromatograms and peak areas for precursor ions from the aspartyl proteases 
(36). To correct for potential differences in protein loading between runs, peak areas were 
normalized by the median peak area of all fragmented ions from that run. The average peak 
area of the precursor ions from a given aspartyl protease was then used to estimate the 
abundance in each cyst fluid sample.
Western blots of gastricsin and cathepsin E
Cyst fluid protein (2 µg) or recombinant protease (20 ng) was pre-incubated for 30 minutes 
in either pH 7.5 phosphate buffer or pH 3.5 acetate buffer. Samples were then subjected to 
electrophoresis on a 10% NuPAGE Bis-Tris gel. Proteins were transferred to polyvinylidene 
fluoride membranes and blocked in Tris-buffered saline with 0.1% Tween (TBS-T) and 5% 
(w/v) non-fat dry milk for 2 hours at room temperature. Membranes were then incubated 
with either rabbit anti-gastricsin antibody (1:500; Abcam, ab104595) or rabbit anti-cathepsin 
E antibody (1:1,000; Abcam, ab49800) for 1 hour at room temperature. Following a wash in 
TBS-T, horseradish peroxidase (HRP)-conjugated secondary antibody (1:15,000; Abcam, 
ab97051) was applied for 2 hours at room temperatures. Proteins were detected with the 
enhanced chemiluminescence (ECL) detection system (Thermo).
Animal strains
The following mice strains were used: Ptf1a-Cre (gift of Christopher Wright, Vanderbilt 
University, Nashville, Tennessee, USA), LSL-KrasG12D (gift of Dave Tuveson, Cold Spring 
Harbor Laboratory, USA), Brg1f/f (gift of David Reisman, University of Florida, USA with 
permission of Pierre Chambon). Mice were crossed on a mixed background. The UCSF 
Institutional Care and Use of Animals Committee (IACUC) approved all mouse 
experiments.
Immunohistochemical analysis of pancreatic tissue
Tissue samples were obtained from patients who underwent resection of pancreatic cystic 
lesions at UCSF. Gastricsin and cathepsin E immunohistochemistry assays were developed 
and performed on a Ventana Discovery Ultra automated slide stainer (Ventana Medical 
Systems). In brief, formalin-fixed, paraffin-embedded (FFPE) samples (4 µm sections) were 
deparaffinized using EZPrep (Ventana Medical Systems) followed by treatment with antigen 
retrieval buffer (Ventana Medical Systems, 950-124). Specimens were incubated with either 
goat anti-gastricsin antibody (1:300; Santa Cruz, sc-51185) or goat anti-cathepsin E 
antibody (1:200; Santa Cruz, sc-6508) for 32 minutes at 36 °C. OmniMap anti-goat 
secondary antibody (Ventana Medical Systems, 760-4647) was then applied for 16 minutes 
before employing a DAB detection kit (Ventana Medical Systems, 760-500). All samples 
were counterstained with haematoxylin and Bluing Reagent (Ventana Medical Systems, 
760-2037). H&E staining of tissue sections was performed using standard protocols.
Mouse pancreatic tissue samples were collected from 8 Ptf1a-Cre; LSL-KrasG12D; Brg1f/f 
animals between 3 and 40 weeks of age. FFPE samples (5 µm sections) were deparaffinized 
with xylene and subsequently rehydrated. Sections were either subjected to H&E staining or 
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heat-induced epitope retrieval with Citra buffer (BioGenex; HK086). Primary antibodies 
(goat anti-mouse) for cathepsin E (1:1,000; R&D Systems; AF1130) and gastricsin (1:1,000; 
Santa Cruz; sc-51188) were incubated with sections overnight at 4 °C. Anti-goat secondary 
antibody (1:200; Vector Labs; BA-9500) was then added to sections for 1 hour at room 
temperature. ABC (Vector Labs; PK-6100) and DAB kits (Vector Labs; SK-4100) were 
employed for detection. Sections were counterstained with haematoxylin and incubated in 
0.25% ammonium hydroxide for bluing.
Peptide synthesis
Synthesis of internally quenched fluorescent peptides was conducted using standard Fmoc 
solid-phase peptide synthesis on a Syro II automated synthesizer (Biotage). Details are 
included in the Supplemental Methods and Materials.
Fluorescent protease activity assays
All fluorescent protease activity assays were performed in triplicate in black, round-bottom 
384 well plates. Assays were run for 1 hour in 15 µL of acetate buffer with 0.01% Tween. 
The pH of the acetate buffer was adjusted to promote activity of either aspartyl protease (pH 
3.5 for the cathepsin E substrate and pH 2.0 for the gastricsin substrate). 10 µM of substrate 
was used for all assays (unless otherwise indicated) and was incubated with either 10 nM of 
recombinant protease or 50 µg/mL of cyst fluid protein. For kinetic analysis of gastricsin 
activity, the substrate concentration ranged from 0.1–25 µM. Fluorescent substrate cleavage 
was monitored with a Biotek Synergy HT plate reader using excitation and emission 
wavelengths of 328 nm and 393 nm, respectively. Selectivity of the recombinant proteases 
was assessed by comparing the initial velocity of substrate hydrolysis in relative fluorescent 
units per second (RFU/sec). For cyst fluid samples, we compared the change in endpoint 
RFU relative to wells that contained substrate, but no cyst fluid.
Statistical analysis and data presentation
A two-tailed Mann-Whitney U test was used to compare the differences in CEA abundance, 
gastricsin activity, and cathepsin E activity between mucinous and nonmucinous cysts. 
Univariate and multivariate logistic regression models were used for cyst prediction. 
Receiver operating characteristic (ROC) curves and Youden’s J statistic were employed to 
identify the optimal cutoff. All mass spectrometry data (spectral counts and peak areas) was 
log2 transformed and analyzed with unpaired two-tailed t-tests. GraphPad Prism was used to 
fit kinetic data and generate scatter plots and bar charts. Volcano plots, heat maps, venn 
diagrams, ROC curves, and logistic regression models were generated in RStudio v. 
0.98.1091. iceLogo software was used to visualize patterns in peptide cleavage sites at ±4 
positions away from the scissile bond (37).
Results
Global protease activity profiling of patient cyst fluid
To identify differences in proteolytic activity between mucinous and nonmucinous cysts we 
used our MSP-MS assay, which is a global and unbiased substrate-based protease profiling 
approach (34). In the MSP-MS assay, a physicochemically diverse library of 228 
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tetradecapeptide substrates is incubated with a protease-containing sample of interest and 
tandem mass spectrometry is used to monitor protease-derived peptide cleavage products. 
We have previously validated this assay through analysis of all classes of protease and used 
it to develop selective substrate probes (38–40).
Using the MSP-MS assay, we profiled 16 mucinous and 7 nonmucinous cyst fluid samples. 
To capture a broad range of protease activities, we performed the assay under acidic 
conditions and at neutral pH. At pH 7.5, we detected a total of 1117 unique peptide 
cleavages among the patient sample set (Fig. 1A). Only 7 peptide cleavages met our 
selectivity criteria for differentiating mucinous from nonmucinous cysts (+/− 1 
log2(mucinous/nonmucinous), p < 0.05). 6 of these cleavages were enriched in nonmucinous 
cysts, and overall, there was a slight trend toward increased proteolytic activity in fluid from 
nonmucinous cysts (Fig. S1A). When the same samples were assayed at pH 3.5, a total of 
691 peptide cleavages were detected, and we observed increased proteolytic activity in the 
mucinous cysts (Fig. 1B and Fig. S1B). All 35 unique substrate cleavages that differentiated 
mucinous from nonmucinous cysts were enriched in the mucinous set. The degree of 
dysplasia within a mucinous cyst is also an important factor in determining whether surgical 
intervention is recommended. However, no major differences in protease activity were 
evident between mucinous cysts with low- or high-grade dysplasia (Fig. S2).
We generated an iceLogo frequency plot to visualize the substrate specificity pattern of the 
35 mucinous-specific peptide cleavages detected at pH 3.5 (Fig. 1C) (37). At the P1 and P1′ 
positions, which flank the cleavage site, there was a predominant enrichment of hydrophobic 
amino acids with the aromatic residues tyrosine and tryptophan more favored at P1. This 
mirrors the previously reported substrate specificity of lysosomal aspartyl proteases (41,42).
Identification of cathepsin E and gastricsin in mucinous cysts
We next sought to identify the specific proteases within the mucinous cysts that are 
responsible for the increased acid-optimal cleavage of the 35 mucinous-specific substrates. 
To aid in the characterization of protease activity, we initially focused on a single mucinous 
cyst fluid sample that cleaved 30 out of the 35 substrates.
We treated the cyst fluid with broad-spectrum inhibitors against all major protease classes 
and analyzed changes in cleavage of the 35 mucinous-specific substrates by MSP-MS (Fig. 
2A). Treatment with the aspartyl protease inhibitor pepstatin fully inhibited cleavage of 20 
mucinous-specific substrates and partially inhibited cleavage of 8 additional substrates. The 
other broad-spectrum protease inhibitors minimally affected cleavage of the mucinous-
specific substrates. The serine protease inhibitor AEBSF and the metal chelator 1,10-
phenanthroline only inhibited cleavage of 3 substrates each. In a second mucinous cyst fluid 
sample, we confirmed that aspartyl protease inhibition with pepstatin blocks cleavage of the 
majority of the mucinous-specific substrates (Fig. S3).
Our inhibition data demonstrated that aspartyl proteases have increased activity in mucinous 
cysts. Therefore, we performed shotgun proteomic analysis of a set of mucinous (n=4) and 
nonmucinous cysts (n=3) to determine if there were differences in the abundance of 
individual aspartyl proteases. This analysis identified three aspartyl proteases – cathepsin D, 
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cathepsin E, and gastricsin (Table S2). Label-free quantitation using precursor ion 
abundance, revealed that cathepsin D was present at similar levels in the mucinous and 
nonmucinous cysts, whereas cathepsin E and gastricsin were significantly more abundant in 
the mucinous cysts (Fig. 2B and Table S3). Aspartyl proteases are synthesized as inactive 
zymogens that undergo enzymatic maturation at an acidic pH (43). As the tumor 
microenvironment is known to be acidic, we investigated whether cathepsin E and gastricsin 
were present in the pro- or mature forms. Exposure of fluid from a mucinous cyst to acidic 
pH induced a mass shift in cathepsin E and gastricsin that was comparable to that observed 
using recombinantly produced proteins (Fig. 2C), indicating that both proteases are released 
into cyst fluid in their proforms. As expected, no cathepsin E or gastricsin was detected in 
fluid from a representative nonmucinous cyst. Collectively, these results demonstrate that the 
proforms of cathepsin E and gastricsin are differentially expressed in mucinous cysts and 
that this induction is responsible for the increased proteolytic activity under acidic 
conditions.
Immunohistochemical analysis of gastricsin and cathepsin E in mucinous cysts
We further examined overexpression of cathepsin E and gastricsin in 14 mucinous cysts 
using immunohistochemical (IHC) analysis. Cytoplasmic gastricsin staining was observed in 
the epithelial cells lining 11 of the 14 mucinous cysts examined (Table S4). Interestingly, 
gastricsin expression was primarily associated with regions of low-grade dysplasia, and no 
staining was observed in regions of high-grade dysplasia (Figs. 3A–D). Gastricsin staining 
was also apparent in areas of low-grade dysplasia within mucinous cysts that contained both 
low- and high-grade dysplasia. Cytoplasmic cathepsin E was detected in all 14 mucinous 
cysts examined; however, staining did not show a dependence on the degree of dysplasia 
(Figs. 3E–H). No gastricsin or cathepsin E staining was evident in the neighboring normal 
ductal epithelium or stromal tissue. In addition, neither protease was detected in either of the 
two nonmucinous SCAs examined.
We also examined expression of gastricsin and cathepsin E in an IPMN genetic mouse 
model. Ptf1a-Cre; LSL-KrasG12D; Brg1f/f mice develop cystic lesions of the pancreas that 
closely resemble human IPMNs (44). Consistent with the above results, we observed 
cytoplasmic gastricsin and cathepsin E staining in the epithelial cells surrounding the cystic 
lesion (Fig. S4). Once again, there was no staining in normal pancreatic tissue.
Development of a gastricsin selective fluorescent substrate
The MSP-MS assay is ideal for discovering global differences in protease activity, but is not 
readily amenable for use as a diagnostic tool. Therefore, we sought to identify sensitive and 
selective fluorescent substrates that could be used in a standard microplate format to 
distinguish mucinous from nonmucinous cysts.
We focused on designing a gastricsin selective substrate as a cathepsin E selective substrate 
has been previously reported (45). We first analyzed the substrate specificity of recombinant 
cathepsin E and gastricsin using the MSP-MS assay (Fig. 4A). We also profiled recombinant 
cathepsin D, as it was detected in cyst fluid samples by our shotgun proteomic analysis (Fig. 
2B), and therefore, we wanted to ensure that the synthesized substrates are not cleaved by 
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this protease. Cathepsins E and D showed highly similar substrate specificity with a Pearson 
correlation coefficient of 0.81 and both proteases displayed a clear preference for 
hydrophobic residues in the P1 and P1′ positions. Gastricsin also preferred hydrophobic 
residues in the P1 and P1′ positions, however, direct comparison of the amino acid 
enrichment profiles revealed that gastricsin also has distinct cleavage preferences (Fig. 4B). 
Most notably, gastricsin shows a significantly stronger preference for tyrosine and 
tryptophan in the P1 position. Gastricsin also slightly favored small amino acids, such as 
glycine, serine, and alanine, in the P1’ position.
Using the MSP- MS assay, we identified 75 peptides that were cleaved by gastricsin and not 
by cathepsins D or E (Fig. 4C). We used the specificity information from Fig. 4A–B to 
select a single peptide substrate that we expected to be highly selective for gastricsin. In 
particular, we chose a peptide that was cleaved by gastricsin with a tryptophan and alanine in 
the P1 and P1′ positions, respectively. We synthesized an internally quenched, fluorescent 
substrate incorporating the P4 to P4′ amino acids from this peptide. This substrate was 
found to be greater than 120-fold selective for gastricsin over both cathepsins D and E (Fig. 
4D) and is cleaved with a kcat/Km of 4.8 × 105 M−1/s−1 (Fig. S5). We also synthesized the 
previously reported cathepsin E selective substrate and confirmed that it is more than 100-
fold selective for cathepsin E over both cathepsin D and gastricsin (Fig. 4D) (45). Lastly, we 
confirmed that we could use these substrates to monitor cathepsin E and gastricsin protease 
activity in cyst fluid. Indeed, both substrates were cleaved in fluid from a mucinous cyst and 
this activity was fully inhibited by pre-incubation with pepstatin (Fig. S6).
Gastricsin and cathepsin E activity differentiate mucinous from nonmucinous cysts
We next used the gastricsin and cathepsin E fluorescent substrates to assess their relative 
protease activities in cyst fluid samples to determine if these activities could be used to 
differentiate mucinous from nonmucinous cysts. We first analyzed the 23 cyst fluid samples 
that we previously profiled using the MSP-MS assay. Cleavage of both the gastricsin and 
cathepsin E substrate was significantly higher in mucinous relative to nonmucinous cysts 
(Fig. S7). This prompted us to assess cathepsin E and gastricsin activity in a validation 
cohort comprised of an additional 87 cyst fluid samples. Again, mucinous cysts displayed 
significantly increased levels of gastricsin and cathepsin E activity (Fig. S7). There were no 
significant differences in activity between the two patient cohorts. Analysis of all 110 patient 
samples revealed that gastricsin activity was on average increased more than 6-fold in 
mucinous cysts, while cathepsin E activity was increased only 2-fold (Fig. 5A–B). The ROC 
curve for gastricsin activity exhibited an area under the curve (AUC) of 0.979 for 
distinguishing mucinous cysts (Fig. 5C and Table S5). At the optimal cutoff of a 1.23-fold 
change in fluorescence, gastricsin activity demonstrated a specificity of 100% and a 
sensitivity of 93%. Cathepsin E activity had an AUC of 0.828 and, using this same optimal 
cutoff, displayed 92% specificity and 70% sensitivity for differentiating mucinous from 
nonmucinous cysts. Gastricsin and cathepsin E activity did not show a dependence on the 
type of mucinous cyst or the degree of dysplasia within a mucinous cyst (Fig. S8). 
Considering that gastricsin expression was only observed in regions of low-grade dysplasia 
(Fig. 3), we were surprised to observe that gastricsin activity was also not associated with 
the degree of dysplasia. This is likely because highly dysplastic and invasive mucinous 
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lesions also often contain regions of low-grade dysplasia. We also examined whether 
gastricsin or cathepsin E activity were correlated with features from the revised Sendai 
criteria, which is a widely applied consensus guidelines for the management of mucinous 
cysts (8). Neither gastricsin nor cathepsin E activity showed significant differences in 
relation to the Sendai features we assessed (Table S6).
CEA levels were independently measured for 89 of the cyst fluid samples, and we compared 
abundance between mucinous (n=55) and nonmucinous cysts (n=34). As expected, CEA was 
significantly elevated in the mucinous cysts (Fig. S9). The CEA ROC curve exhibited an 
AUC of 0.865 for distinguishing mucinous cysts from nonmucinous cysts (Fig. 5C). CEA-
based classification underperformed gastricsin activity, but was comparable to cathepsin E 
activity-based classification. For CEA, a cutoff level of 192 ng/mL is the commonly used 
clinical standard for differentiating mucinous from nonmucinous cysts (46). At this cutoff, 
CEA demonstrated a specificity of 94% and a sensitivity of 65%, which is consistent with 
what has been previously reported. All 19 of the mucinous cyst fluid samples with CEA 
levels below the standard cutoff of 192 ng/mL were correctly classified by gastricsin activity. 
Additionally, the two nonmucinous cysts with CEA levels above 192 ng/mL were also 
correctly classified by gastricsin activity.
We also assessed whether combined analysis of CEA with gastricsin and cathepsin E activity 
could better differentiate mucinous from nonmucinous cysts. Gastricsin activity with CEA 
evaluation resulted in a classifier with an AUC of 0.998 (Fig. 5C), exhibiting a specificity of 
100% and sensitivity of 98%. Inclusion of all three markers did not lead to improved 
differentiation of mucinous from nonmucinous cysts (Table S5).
Discussion
Although pancreatic cysts are being detected at an increasing rate, available diagnostic tests 
do not accurately discriminate between cyst types. Mucinous cysts have malignant potential 
and may require resection, while nonmucinous cysts are considered benign and require no 
further evaluation if these lesions are asymptomatic. Increasing the level of certainty in this 
distinction would spare some patients unnecessary surgical resections and reduce the need 
for ongoing surveillance for many more individuals. In this study, we used an unbiased and 
global substrate-based profiling strategy coupled with proteomics, to identify distinguishing 
protease activities in cyst fluid samples. Using this approach, gastricsin and cathepsin E 
activities were found to be promising markers for differentiating benign nonmucinous cysts 
from potentially malignant mucinous cysts. Selective fluorescent substrates both confirmed 
induction of these proteases in mucinous cysts and enabled sensitive and specific 
differentiation of these lesions in 110 patient samples.
To date, CEA remains the most widely used clinical biomarker for differentiating mucinous 
from nonmucinous cysts. However, the performance of this marker is generally considered 
suboptimal. Indeed, CEA analysis was only 76% accurate in our study at the standard cutoff 
of 192 ng/mL. Gastricsin activity was 95% accurate, and correctly classified all 21 cysts that 
were misclassified by CEA, clearly demonstrating the clinical utility of this marker. 
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Furthermore, we were able to improve classification accuracy to 99% by combining CEA 
with gastricsin activity analysis.
Preoperatively determining the degree of dysplasia within a mucinous cyst is another major 
challenge for ensuring appropriate clinical intervention. However, the protease activity 
markers identified in this study do not differentiate between mucinous cysts with low- or 
high-grade dysplasia. Although this is a limitation of our markers, correctly differentiating 
mucinous from nonmucinous cysts is a critical first step in deciding which cysts should 
undergo resection. For example, pancreatic resection of the 39 benign nonmucinous cysts 
included in this study could potentially have been avoided through the application of our 
assay. In addition, 19 mucinous cysts within our patient cohort had CEA levels below the 
standard cutoff of 192 ng/mL. In our high-volume pancreatic centers, radiographic and 
clinical features allowed experienced clinicians to correctly identify these cysts as mucinous. 
However, medical centers without dedicated cyst specialists may be inclined to misclassify 
these samples as nonmucinous and would greatly benefit from our simple and accurate 
diagnostic assay. A number of molecular and clinical markers have recently shown promise 
for distinguishing mucinous cysts based on their degree of dysplasia (19,23). A sequential 
diagnostic strategy may emerge in which gastricsin and cathepsin E activity are used to 
determine if a lesion is mucinous, followed by analysis of a secondary marker to define the 
degree of dysplasia. Assessing gastricsin and cathepsin E activity in combination with other 
promising markers will be a primary focus of future work.
Previous gene expression profiling studies of IPMNs and MCNs demonstrated 
overexpression of gastricsin and cathepsin E mRNA (29–31). However, the protein levels 
and activity of these aspartyl proteases has not been previously investigated within these 
lesions. Protease activity is particularly well suited to the development of a rapid and simple 
diagnostic test for differentiating cysts. Activity-based detection is highly sensitive because 
of catalytic signal amplification. Indeed, the assays described in this study use less than 5 µL 
of cyst fluid, whereas CEA tests often require at least 500 µL. Furthermore, unlike 
immunoassays, protease activity assays do not require the costly development of high-
quality antibody reagents. Spectrophotometric assays can be readily adapted to the standard 
plate readers present in clinical laboratories, and there are already several examples of such 
protease activity assays in common clinical use for other indications (47,48).
We were particularly interested to observe that gastricsin expression within mucinous cysts 
was primarily associated with areas of low-grade dysplasia and was absent in high-grade 
dysplasia, although we were only able to assess four cysts containing regions of high-grade 
dysplasia. Previous work demonstrated that gastricsin and other foregut markers are 
overexpressed in other pancreatic cancer precursor lesions, reflecting a cellular 
dedifferentiation step prior to malignant transformation (49). Gastricsin overexpression 
within IPMNs and MCNs might be reflective of a similar process. In support of this 
hypothesis, recent work using the same IPMN genetic mouse model examined in this study 
showed that cellular dedifferentiation is a critical step in the development of IPMNs (44,50). 
Dedifferentiation within this genetic mouse model is transient and occurs prior to the 
development of invasive cancer, which may explain why gastricsin expression is associated 
with regions of low-grade dysplasia. In contrast to gastricsin, we did not observe an 
Ivry et al. Page 11
Clin Cancer Res. Author manuscript; available in PMC 2018 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
association between cathepsin E expression and the degree of dysplasia present within a 
mucinous cyst. This suggests that different processes control the expression of these two 
proteases and that cathepsin E levels are less reflective of cellular identity. Additional studies 
using the recently developed genetic mouse models of mucinous cysts are needed to 
characterize how the expression of these proteases is regulated and what roles – if any – 
gastricsin and cathepsin E are playing in neoplastic transformation (44).
In summary, our results demonstrate that gastricsin and cathepsin E activity are sensitive and 
specific markers for differentiating mucinous from nonmucinous pancreatic cystic lesions. In 
particular, gastricsin activity is a promising candidate for the development of a simple, 
diagnostic test with superior performance to CEA. This could provide clinical stratification 
to properly manage the growing problem of pancreatic cysts.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Translational relevance
With advances in abdominal imaging technologies, the incidental detection of pancreatic 
cysts continues to rise. However, there remains a lack of accurate molecular diagnostics 
for differentiating benign cystic lesions from those that can progress into pancreatic 
cancer. This has led to a dramatic increase in the number of potentially unnecessary 
pancreatic resections, which are associated with high rates of morbidity. Using a global 
and unbiased protease-activity profiling approach and patient cyst fluid, we determined 
that the activities of the aspartyl proteases gastricsin and cathepsin E accurately 
differentiate premalignant mucinous cysts from benign nonmucinous cysts. In particular, 
analysis of gastricsin activity demonstrated 93% sensitivity and 100% specificity for 
differentiating mucinous lesions. Our simple and direct fluorescence-based approach for 
stratification of pancreatic cysts significantly outperformed the most widely used 
molecular biomarker – carcinoembryonic antigen (CEA) – and can be readily translated 
into an actionable diagnostic assay to help improve clinical management of these 
challenging lesions.
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Fig. 1. Comparison of global proteolytic activity in mucinous and nonmucinous cysts by MSP-
MS
Volcano plots displaying the peptide cleavages generated by mucinous (n=16) and 
nonmucinous cysts (n=7) when assayed at pH 7.5 (A) or pH 3.5 (B). Spectral counts of 
peptide cleavage products were used for relative quantification of the fold change 
(mucinous/nonmucinous) and hypothesis testing. Cleavages that met the criteria for 
differentiating mucinous from nonmucinous cysts (+/− 1 log2(fold change), p < 0.05) are 
shown in blue. The substrate specificity of the cleavages within the red box is displayed with 
an iceLogo plot (C). Residues shown are statistically significant with p < 0.05.
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Fig. 2. Identification of enriched aspartyl protease activity in mucinous cysts
(A) Heatmap displaying cleavage of 30 mucinous-specific substrates following treatment of 
a mucinous cyst fluid sample with DMSO or various broad-spectrum protease inhibitors. 
Spectral counts were used for relative quantification of peptide cleavage products. Vertical 
bar (|) indicates the site of cleavage within substrates. (B) Label-free quantitation of aspartyl 
protease relative abundance in mucinous (M) and nonmucinous (NM) cysts. (C) Western 
blot analysis of recombinant (r) and cyst fluid-derived cathepsin E and gastricsin. Samples 
were pre-incubated at the indicated pH for 10 minutes.
Ivry et al. Page 18
Clin Cancer Res. Author manuscript; available in PMC 2018 August 15.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Fig. 3. Immunohistochemical analysis of gastricsin and cathepsin E in mucinous cysts
Histological analysis of mucinous cysts with low-grade dysplasia (A, B, E, F) and high-
grade dysplasia (C, D, G, H). Gastricsin (A, C), cathepsin E (E, G), and haematoxylin and 
eosin (H&E) staining (B, D, F, H) in IPMNs (A–F) and MCNs (G, H). Scale bar is 10 µm.
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Fig. 4. Design and synthesis of gastricsin selective fluorescent substrate
(A) Substrate specificity of cathepsin D, cathepsin E, and gastricsin as determined by MSP-
MS. Residues shown in iceLogo are statistically significant with p < 0.05. (B) Heatmap 
comparing the amino acid enrichment Z-scores for gastricsin relative to cathepsin D and 
cathepsin E. (C) Venn diagram depicting the unique and overlapping cleavages detected by 
MSP-MS with cathepsin D, cathepsin E, and gastricsin. (D) Cleavage of the fluorescent 
substrates by cathepsin D, cathepsin E, and gastricsin. Activity was normalized to 1.00 
based on the maximal activity against each substrate. Red arrow indicates the site of 
cleavage. Error bars denote standard error of the mean (SEM) from triplicate analysis.
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Fig. 5. Quantification of gastricsin and cathepsin E activity in 110 cyst fluid samples
Analysis of gastricsin (A) and cathepsin E (B) activity in nonmucinous (NM) and mucinous 
(M) cysts using fluorescent substrates. (C) ROC curves comparing sensitivity and specificity 
of CEA, gastricsin, cathepsin E, and CEA and gastricsin in combination.
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